<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30179299</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1582-4934</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>04</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of cellular and molecular medicine</Title>                <ISOAbbreviation>J. Cell. Mol. Med.</ISOAbbreviation>            </Journal>            <ArticleTitle>Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.13719</ELocationID>            <Abstract>                <AbstractText>Oestrogen receptor (ER) is expressed in approximately 60%-70% of human breast cancer. Clinical trials and retrospective analyses have shown that ER-positive (ER+) tumours are more tolerant to chemotherapeutic drug resistance than ER-negative (ER-) tumours. In addition, isobavachalcone (IBC) is known as a kind of phytoestrogen with antitumour effect. However, the underlying mechanism of IBC in ER+ breast cancer needs to be elucidated further. Our in vitro experiments showed that IBC could attenuate 17β-estradiol (E<sub>2</sub> )-induced paclitaxel resistance and that E<sub>2</sub> could stimulate CD44 expression in ER+ breast cancer cells but not in ER- cells. Meanwhile, E<sub>2</sub> could promote ERα expression to render ER+ breast cancer cells resistant to paclitaxel. Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERα in the enhancement of paclitaxel resistance via the regulation of CD44 transcription. IBC down-regulated ERα and CD44 expression and thus inhibited tumour growth in paclitaxel-resistant xenograft models. Overall, our data demonstrated for the first time that IBC could decrease CD44 expression level via the ERα pathway and make ER+ breast cancer cells sensitive to paclitaxel treatment.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Junfeng</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Clinical Research Center, Xuyi People's Hospital, Xuyi, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Yi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing Pukou Central Hospital, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Wenxing</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>School of pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tang</LastName>                    <ForeName>Cuiju</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Honghong</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Yuetong</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Xiuwei</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Zhi</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Jingsun</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Jinfei</ForeName>                    <Initials>J</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5874-3462</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Nanjing First Hospital, NanJing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Clinical Research Center, Xuyi People's Hospital, Xuyi, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>YKK14081</GrantID>                    <Agency>the project of Science &amp; Technology of Nanjing</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>BK20150092</GrantID>                    <Agency>the Natural Science Foundation of Jiangsu Province</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>81502623</GrantID>                    <Agency>the National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>BE2017611</GrantID>                    <Agency>the Key R &amp; D Special Fund of Jiangsu Province</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Cell Mol Med</MedlineTA>            <NlmUniqueID>101083777</NlmUniqueID>            <ISSNLinking>1582-1838</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">CD44</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">isobavachalcone</Keyword>            <Keyword MajorTopicYN="N">oestrogen receptor alpha</Keyword>            <Keyword MajorTopicYN="N">paclitaxel resistance</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>05</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30179299</ArticleId>            <ArticleId IdType="doi">10.1111/jcmm.13719</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>